Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | LPL | P06858 | 2/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15985302 | 0.96 | SMN1; SMN2 (0.68) | SMN1; SMN2NAAAL3MBTL1GAAMAPT | |
| SCHEMBL1233804 | 0.91 | L3MBTL1 (0.65) | SMN1; SMN2NAAAL3MBTL1GAAMAPT | |
| SCHEMBL15985327 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2NAAAL3MBTL1GAAMAPT | |
| SCHEMBL15985331 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2NAAAL3MBTL1TP53BP1HDAC1 | |
| SCHEMBL16117373 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NAAAL3MBTL1GAAMAPT | |
| SCHEMBL15985415 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2NAAAL3MBTL1TP53BP1HDAC1 | |
| SCHEMBL14483776 | 0.86 | ALDH1A1 (0.60) | SMN1; SMN2GAAMAPTALDH1A1POLB | |
| SCHEMBL2555189 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1TP53BP1LMNA | |
| SCHEMBL2454819 | 0.85 | HPGD (0.53) | SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL3031782 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1GAAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9012651-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-6919382-B2 | Preparation and uses of conjugated solid supports for boronic acids | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2005-07-19 | — | — | US | disclosed |
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, TSLP, IFNG | SMN1; SMN2 4726/4885NAAA 3799/4885L3MBTL1 2951/4885 |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | SMN1; SMN2 4065/4885NAAA 1634/4885L3MBTL1 2979/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | SMN1; SMN2 2358/4885NAAA 33/4885L3MBTL1 4638/4885 |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | SMN1; SMN2 4365/4885NAAA 2734/4885L3MBTL1 2691/4885 |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | FAAH, FAAH2, ASAH1 | SMN1; SMN2 2045/4885NAAA 23/4885L3MBTL1 4745/4885 |
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | SLC43A1, SBDS, SLC7A5 | SMN1; SMN2 3648/4885NAAA 1147/4885L3MBTL1 3686/4885 |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | SMN1; SMN2 3309/4885NAAA 3931/4885L3MBTL1 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.